This compound plays the role of a “decoy receptor” for BAFF and APRIL [34] by binding soluble and membrane-bound forms of BAFF and APRIL [12,32,33] and it is being evaluated as a treatment option for SLE patients [33,35]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.